Previous 10 | Next 10 |
2024-06-04 09:00:00 ET Summary Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline....
2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...
2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...
2024-06-01 14:44:45 ET More on etc. ARKK - Risky Does Not Equal Reward Canadian Tire Offers A Good Earnings Yield Despite Temporary Slowdown DAPP: Crypto Stocks Lose Some Luster In 2024 As New ETFs Capture The Spotlight Delta summer demand 'quite healthy' - C...
2024-06-01 13:30:00 ET More on BioNTech BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript BioNTech: Undecided Between A One Trick Pony And A Full-Fledged Pharma Company BioNTech gains antibody drug ...
2024-06-01 08:19:05 ET More on Akeso, Summit Therapeutics, etc. Summit Therapeutics Stock: Plunging Despite A Win? Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit p...
2024-06-01 05:30:37 ET Summary Ocular Therapeutix has provided promising updates on its clinical trials for Axpaxli and Paxtrava, utilizing its Elutyx drug-eluting platform. The company has appointed a new CEO and raised funds, extending its cash runway until 2028. Ocular's pi...
2024-05-31 16:31:58 ET More on Immunocore Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M Cantor sees strong year ahead for oncology M&A Seeking Alpha’s Quant Rating on Immunocore Historical earnings data for Immuno...
2024-05-31 09:27:30 ET Summary Summit Therapeutics has achieved massive market success in 2024, with a market capitalization of over $7 billion. Summit's main pipeline candidate is ivonescimab, a bispecific antibody targeting both PD-1 and VEGF. Ivonescimab has shown "decisive...
2024-05-31 08:59:26 ET More on Akeso, Merck, etc. Merck Stock: Still Discounted To Graham P/E Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Merck: The Worst Has Been Avoided (Rating Upgrade) Dividend Roundup: Meta Platfo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...
How one employee's upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she's done across industries. As a young...
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced upcoming data presentations and programming at the 25 th International ...